144 related articles for article (PubMed ID: 35984342)
21. Soluble PD-L1 as a predictive biomarker in lung cancer: a systematic review and meta-analysis.
Cheng Y; Wang C; Wang Y; Dai L
Future Oncol; 2022 Jan; 18(2):261-273. PubMed ID: 34874185
[TBL] [Abstract][Full Text] [Related]
22. Prognostic value of programmed cell death ligand-1 expression in ovarian cancer: an updated meta-analysis.
Piao J; Lim HJ; Lee M
Obstet Gynecol Sci; 2020 May; 63(3):346-356. PubMed ID: 32489980
[TBL] [Abstract][Full Text] [Related]
23. Predictive effect of PD-L1 expression for immune checkpoint inhibitor (PD-1/PD-L1 inhibitors) treatment for non-small cell lung cancer: A meta-analysis.
Zhang B; Liu Y; Zhou S; Jiang H; Zhu K; Wang R
Int Immunopharmacol; 2020 Mar; 80():106214. PubMed ID: 31982822
[TBL] [Abstract][Full Text] [Related]
24. High PD-L1 expression in the tumour cells did not correlate with poor prognosis of patients suffering for oral squamous cells carcinoma: A meta-analysis of the literature.
Troiano G; Caponio VCA; Zhurakivska K; Arena C; Pannone G; Mascitti M; Santarelli A; Lo Muzio L
Cell Prolif; 2019 Mar; 52(2):e12537. PubMed ID: 30443950
[TBL] [Abstract][Full Text] [Related]
25. Role of programmed cell death ligand-1 expression on prognostic and overall survival of breast cancer: A systematic review and meta-analysis.
Li S; Chen L; Jiang J
Medicine (Baltimore); 2019 Apr; 98(16):e15201. PubMed ID: 31008945
[TBL] [Abstract][Full Text] [Related]
26. Increased programmed death ligand-1 expression predicts poor prognosis in hepatocellular carcinoma patients.
Gu X; Gao XS; Xiong W; Guo W; Han L; Bai Y; Peng C; Cui M; Xie M
Onco Targets Ther; 2016; 9():4805-13. PubMed ID: 27536144
[TBL] [Abstract][Full Text] [Related]
27. Expression of Programmed Cell Death Ligand 1 as a Predictive Biomarker in Metastatic Urothelial Carcinoma Patients Treated with First-line Immune Checkpoint Inhibitors Versus Chemotherapy: A Systematic Review and Meta-analysis.
Rizzo A; Mollica V; Massari F
Eur Urol Focus; 2022 Jan; 8(1):152-159. PubMed ID: 33516645
[TBL] [Abstract][Full Text] [Related]
28. Prognostic and Clinicopathological Value of PD-L1 in Melanoma: A Meta-Analysis.
Xu J; Wang F; Yan Y; Zhang Y; Du Y; Sun G
Am J Med Sci; 2020 Jun; 359(6):339-346. PubMed ID: 32498941
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of PD-1/PD-L1 inhibitors in triple-negative breast cancer: a systematic review and meta-analysis.
Zhang M; Song J; Yang H; Jin F; Zheng A
Acta Oncol; 2022 Sep; 61(9):1105-1115. PubMed ID: 35939538
[TBL] [Abstract][Full Text] [Related]
30. Prognostic Value of Programmed Cell Death Ligand-1 Expression in Nasopharyngeal Carcinoma: A Meta-Analysis of 1,315 Patients.
Liu X; Shan C; Song Y; Du J
Front Oncol; 2019; 9():1111. PubMed ID: 31709181
[No Abstract] [Full Text] [Related]
31. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
32. Prognostic value of PD-L1 expression in tumor infiltrating immune cells in cancers: A meta-analysis.
Zhao T; Li C; Wu Y; Li B; Zhang B
PLoS One; 2017; 12(4):e0176822. PubMed ID: 28453554
[TBL] [Abstract][Full Text] [Related]
33. Clinicopathological and prognostic significance of PD-L1 expression in colorectal cancer: a meta-analysis.
Wang S; Yuan B; Wang Y; Li M; Liu X; Cao J; Li C; Hu J
Int J Colorectal Dis; 2021 Jan; 36(1):117-130. PubMed ID: 32910207
[TBL] [Abstract][Full Text] [Related]
34. Prevalence and prognostic role of PD-L1 in patients with gynecological cancers: A systematic review and meta-analysis.
Fu H; Fu Z; Mao M; Si L; Bai J; Wang Q; Guo R
Crit Rev Oncol Hematol; 2023 Sep; 189():104084. PubMed ID: 37536446
[TBL] [Abstract][Full Text] [Related]
35. Prognostic value of lactate dehydrogenase for melanoma patients receiving anti-PD-1/PD-L1 therapy: A meta-analysis.
Xu J; Zhao J; Wang J; Sun C; Zhu X
Medicine (Baltimore); 2021 Apr; 100(14):e25318. PubMed ID: 33832106
[TBL] [Abstract][Full Text] [Related]
36. Relationship of programmed death ligand-1 expression with clinicopathological features and prognosis in patients with oral squamous cell carcinoma: A meta-analysis.
He J; Chen XF; Xu MG; Zhao J
Arch Oral Biol; 2020 Jun; 114():104717. PubMed ID: 32344357
[TBL] [Abstract][Full Text] [Related]
37. Association between programmed cell death ligand 1 expression and thyroid cancer: A meta-analysis.
Wan B; Deng P; Dai W; Wang P; Dong Z; Yang C; Tian J; Hu T; Yan K
Medicine (Baltimore); 2021 Apr; 100(14):e25315. PubMed ID: 33832105
[TBL] [Abstract][Full Text] [Related]
38. The prediction potential of neutrophil-to-lymphocyte ratio for the therapeutic outcomes of programmed death receptor-1/programmed death ligand 1 inhibitors in non-small cell lung cancer patients: A meta-analysis.
Huang Y; Shen A
Medicine (Baltimore); 2020 Aug; 99(34):e21718. PubMed ID: 32846790
[TBL] [Abstract][Full Text] [Related]
39. The clinicopathological significance and prognostic value of programmed death-ligand 1 in prostate cancer: a meta-analysis of 3133 patients.
Shen H; Liu J; Sun G; Yan L; Li Q; Wang Z; Xie L
Aging (Albany NY); 2020 Dec; 13(2):2279-2293. PubMed ID: 33318295
[TBL] [Abstract][Full Text] [Related]
40. Prognostic and clinicopathological value of PD-L1 expression in primary breast cancer: a meta-analysis.
Huang W; Ran R; Shao B; Li H
Breast Cancer Res Treat; 2019 Nov; 178(1):17-33. PubMed ID: 31359214
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]